Procter & Gamble’s psyllium cholesterol-lowering claim
Executive Summary
Via a May 11 letter, FDA gives the go-ahead for use of a protocol for a 34-week, double-blind, placebo-controlled, multisite, parallel, clinical study of psyllium's effect on reducing cholestrol levels. P&G, marketer of the psyllium-containing laxative Metamucil, previously submitted data on psyllium which FDA determined was insufficient to support a cholesterol-lowering claim. FDA said that the study objectives "are clear and the protocol should provide adequate data for statistical analysis of end-point efficacy and safety variables." But FDA added that the study "is not intended to address the questions of dose response and mechanism of action" and the agency made suggestions for minor modifications.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.